On the 24th and 25th April, more than 50 representatives of TransBioLine partners had the opportunity to meet in Amsterdam during the 6th TransBioLine Consortium Meeting.
After sharing the current financial status of the project and the communication activities performed during the last months, an interesting and insightful discussion on the definition of the next steps to secure project sustainability was led by Sophia Samodelov, the project coordinator.
During this 2-day meeting, participants also had the opportunity to attend a symposium on miRNA NGS data analysis, discuss regulatory strategies, and exchange and align within 5 individual organ work package meetings. Work package 2 (Drug-Induced Liver Injury) was able to share their learning phase datasets and each team shared “elevator pitches”, sharing their next steps and 2023-2024 activities. Main goals for this year, including continuing to improve communication across partners, are to complete the learning phase data analysis and interpretation and to take the next steps in our regulatory submissions and interactions with the EMA and FDA.
To conclude the 6th Consortium Meeting, Anne Cambon-Thomsen, James Dear, Magnus Ingelman-Sundberg, Chris Leptak, and Paul Watkins, members of the TransBioLine Scientific and Ethical advisory boards, shared their thoughts on the project progression and provided additional guidance on how to achieve TransBioLine goals.
“TransBioLine is an impressively broad project, whose outcomes will have an impact on drug regulation.” P. Watkins
Thanks to all the TransBioLine partners for another fruitful event and look forward to meeting again in October for the 7th Consortium Meeting in Basel!